Empower the potential of trastuzumab deruxtecan with novel combinations.

Christian D Rolfo Marzia Del Re Alessandro Russo

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Trastuzumab deruxtecan (T-DXd) is reshaping the therapeutic landscape of HER2-positive tumors. A recent article reports on the preclinical activity of the combination of T-DXd plus adavosertib, WEE1 kinase inhibitor, which promises to expand the use of this antibody-drug conjugate in HER2-positive tumors with CCNE1 co-amplification.

Keyphrases

epidermal growth factor receptor
metastatic breast cancer
single cell
stem cells
emergency department
cancer therapy
mesenchymal stem cells
drug induced